Quantbot Technologies LP Purchases 1,384 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantbot Technologies LP boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 678.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,588 shares of the biopharmaceutical company’s stock after acquiring an additional 1,384 shares during the quarter. Quantbot Technologies LP’s holdings in Alnylam Pharmaceuticals were worth $374,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Cerity Partners LLC grew its position in Alnylam Pharmaceuticals by 133.6% during the 3rd quarter. Cerity Partners LLC now owns 13,019 shares of the biopharmaceutical company’s stock worth $3,581,000 after acquiring an additional 7,445 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $45,000. Bridgewater Associates LP bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $551,000. Blueshift Asset Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $293,000. Finally, Captrust Financial Advisors raised its holdings in Alnylam Pharmaceuticals by 34.4% in the 3rd quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after buying an additional 1,237 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 0.9 %

Shares of ALNY stock opened at $268.46 on Friday. The stock’s 50-day moving average price is $259.86 and its 200-day moving average price is $260.50. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market capitalization of $34.92 billion, a price-to-earnings ratio of -123.71 and a beta of 0.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on ALNY shares. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 21st. Sanford C. Bernstein reduced their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $312.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.